Aromatase inhibitor-induced musculoskeletal symptoms in foot and ankle surgery

Approximately 4,700 Danish women are diagnosed with breast cancer annually [1]. In the majority, either oestrogen receptor or progesterone receptor is overexpressed, promoting the development of breast cancer [2]. Thus, various hormone receptor-targeted therapies such as aromatase inhibitors (AI), e.g., anastrozole and letrozole, have been developed [3]. In postmenopausal women, AIs are the cornerstone for managing hormone receptor-positive breast cancer [4].